Izalontamab is under clinical development by Systimmune and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II drugs for Oropharyngeal Cancer have a 50% phase transition ...
Ibotta (NYSE: IBTA) landed at No. 10 on the PitchBook list. Ahead of it were companies like SystImmune Inc., a Redmund, Washington-based biotechnology company with an $8.4 billion exit via an ...
BLM-07D1 is under clinical development by Systimmune and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition success rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback